Tisocalcitate

Drug Profile

Tisocalcitate

Alternative Names: Psoriasis therapy - Bayer Schering Pharma

Latest Information Update: 22 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Class Antipsoriatics; Vitamin D analogues
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
  • 03 Mar 2004 Data presented at the 62nd Annual Meeting of the American Academy of Dermatology (AAD-2004) have been added to the adverse events and pharmacokinetics sections ,
  • 12 May 2003 Phase-II clinical trials in Psoriasis in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top